YouTube · Q2 2026 · 2026-08-01
GRFS · NasdaqGS
Grifols, S.A.
Drug Manufacturers - General · Spain
USD 7.31-1.2% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$4.98B
- Trailing P/E
- 9.62x
- Forward P/E
- 5.07x
- Quarterly revenue growth
- -0.9%
- Trailing net margin
- 6.1%
- Indicated dividend yield
- 3.8%
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Company background
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Company websiteH1 2026
Go beyond the headline.
Grifols (GRFS): Profit Jumped 29% — Until You Find the €109M Accounting Gain
Published 2026-07-29
Comparable businesses
GRFS peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | GRFSGrifols, S.A.Snapshot 2026-09-20Financial period: 2026-06-30 | OGNOrganon & Co.Snapshot 2026-09-20Financial period: 2026-06-30 | BIIBBiogen Inc.Snapshot 2026-09-20Financial period: 2026-06-30 |
|---|---|---|---|
| Market capMarket value, converted to USD | US$4.98B | US$3.59B | US$31.84B |
| Forward P/EProvider forward earnings estimate | 5.07x | 3.78x | 13.03x |
| EV / EBITDAEnterprise value / trailing EBITDA | — | 7.04x | 11.58x |
| Revenue growthLatest quarter vs prior-year quarter | -0.9% | -2.3% | 3.4% |
| Operating marginLatest reported quarter | 15.9% | 20.7% | 25.1% |
| Free cash flow yieldTrailing cash flow / market cap | — | 13.7% | 4.0% |
| Net debt / EBITDANet debt / trailing EBITDA | 5.36x | 4.74x | 2.10x |
| Debt / equityTotal debt / positive book equity | 1.17x | 8.50x | 0.44x |
| Trailing P/ETrailing twelve-month earnings | 9.62x | 17.54x | 38.35x |
| Price / bookPrice / positive book equity per share | 1.55x | 3.57x | 1.69x |
| EV / salesEnterprise value / trailing revenue | — | 1.80x | 3.88x |
| Earnings growthLatest quarter vs prior-year quarter | 32.9% | -28.3% | -84.8% |
| Gross marginTrailing twelve months | 37.8% | 53.4% | 78.3% |
| Net marginTrailing twelve months | 6.1% | 3.4% | 8.3% |
| Return on equityProvider trailing return; positive equity only | 6.9% | 24.0% | 4.6% |
| Free cash flow marginTrailing free cash flow / revenue | 7.7% | 8.0% | 12.6% |
| Dividend yieldIndicated annual dividend / price | 3.8% | 0.6% | — |
| Earnings payoutProvider trailing dividend payout | 36.8% | 10.3% | 0.0% |
| Current ratioCurrent assets / current liabilities | 2.37x | 1.95x | 1.86x |
| BetaProvider historical market sensitivity | 1.19 | 1.52 | 0.17 |
YouTube · Q2 2026 · 2026-08-01
YouTube · Q1 2026 · 2026-04-29
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for GRFS
H1 20262026-07-29
Grifols (GRFS): Profit Jumped 29% — Until You Find the €109M Accounting Gain
Presentation · 2026-07-29 · YouTube